Comparison of Rituximab Versus Bortezomib-Based Regimens in Patients with Lymphoplasmacytic Lymphoma
Objective To evaluate the efficacy of rituximab based regimen and bortezomib based regimen in lymphoplasmacytic lymphoma.Methods A retrospective analysis was performed on 48 patients with lymphoplasmacytic lymphoma treated in the First Affiliated Hospital of Xinxiang Medical College from October 2018 to December 2022.Among them,rituximab was the main treatment group(23 cases)and bortezomib was the main chemotherapy group(25 cases).Objective response rate and progression free survival(PFS)were compared between the two groups,and the occurrence of adverse reactions during treatment was observed between the two groups.Results There was no significant difference in remission rate between rituximab chemotherapy regimen and bortezomib chemotherapy regimen(P＞0.05),but the duration of PFS in rituximab chemotherapy regimen was longer than that in bortezomib chemotherapy regimen(P＜0.05).The side effects of rituximab were mainly hemocytopenia and infection.The side effects of bortezomib-based chemotherapy were mainly peripheral nerve injury and digestive tract reaction constipation and diarrhea.Conclusion Rituximab and bortezomib can be used in the treatment of lymphoplasmacytic lymphoma,but the advantages and disadvantages of the two groups are different.
万方数据
维普
